Back to News

Categories: News | Published On: December 14, 2023 | Written by Brandon Tilley |

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

Back to News
More News
  • Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
    Read More
  • Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany.
    Read More
BUSINESS AND MEDIA INQUIRIES

Micah Pearlman
micah@biolojic.com